The person added that there were no safety-related concerns about the vaccine candidate and it has also shown an efficacy of over 91 per cent.
“There were no cases of any serious adverse events. Fever was the most common side-effect cured easily with paracetamol. However, we wanted to have comparative immunogenicity data between the Russian and Indian volunteers and more details on the neutralising antibody titers,” said the source.
Sputnik V is a heterogenous vaccine, using two different virus strains or antigens in its two doses. The first dose uses human adenovirus (a common flu virus) type 26 (Ad26), which is the same as that used by Johnson & Johnson (J&J) in its single shot vaccine.
J&J vaccine has 85 per cent efficacy against severe disease after 28 days. DRL and Russian sovereign wealth fund Russian Direct Investment Fund (RDIF) have claimed that Sputnik V would show efficacy from Day 28 and peak by Day 42.
The second shot of the vaccine will use adenovirus type 5 (Ad5). In order to differentiate between the two doses — primer and booster — the colours of the vaccine will be different. The colours will be distinct to avoid confusion among vaccinators.
By deploying two different vectors, Sputnik V avoids a possible neutralising effect and generates a durable and longer-lasting immune response, claimed RDIF.
DRL has indicated it would provide the cold chain solution for Sputnik V. It requires minus 18 degrees Celsius to remain stable. Details of the cold chain plan, however, were not provided, claimed sources.
Earlier RDIF had noted: “Due to the time needed for the immune response to develop, in the first week after vaccination there was no significant difference in protection against severe cases of Covid-19 between the vaccine and the placebo groups. In the period from 7 to 14 days, the vaccine’s efficacy rose to 50 per cent. In the period from 14 to 21 days to 74.1 per cent, and to 100 per cent from Day 21, giving full protection against severe cases of the coronavirus.”
“RDIF confirms it is awaiting the recommendation by the subject expert committee of the Central Drugs Standard Control Organisation to approve the use of the Sputnik V in India,” a spokesperson for RDIF said on Monday.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.